A recent phase II clinical trial results suggest that the monoclonal antibody hu14.18K322A could help change treatment of children with high-risk neuroblastoma.
from Top Health News -- ScienceDaily https://ift.tt/3Is7pm2
Health, Fitness,Dite plan, health tips,athletic club,crunch fitness,fitness studio,lose weight,fitness world,mens health,aerobic,personal trainer,lifetime fitness,nutrition,workout,fitness first,weight loss,how to lose weight,exercise,24 hour fitness,
Post a Comment